Plasmodium vivax shows a strict host tropism for reticulocytes. We identified transferrin receptor 1 (TfR1) as the receptor for P. vivax reticulocyte-binding protein 2b (PvRBP2b). We determined the structure of the N-terminal domain of PvRBP2b involved in red blood cell binding, elucidating the molecular basis for TfR1 recognition. We validated TfR1 as the biological target of PvRBP2b engagement by means of TfR1 expression knockdown analysis. TfR1 mutant cells deficient in PvRBP2b binding were refractory to invasion of P. vivax but not to invasion of P. falciparum. Using Brazilian and Thai clinical isolates, we show that PvRBP2b monoclonal antibodies that inhibit reticulocyte binding also block P. vivax entry into reticulocytes. These data show that TfR1-PvRBP2b invasion pathway is critical for the recognition of reticulocytes during P. vivax invasion.
O f the hundreds of Plasmodium species, only P. falciparum, P. vivax, P. ovale curtisi, P. ovale wallikeri, P. malariae, and P. knowlesi are known to infect humans. Within the human host, malaria parasites invade liver and red blood cells for replication and transmission. Blood stage infection is the major cause of all clinical symptoms in malaria, and therefore the therapeutic prevention of parasite entry into red blood cells could alleviate malarial disease. Entry into red blood cells depends on the interactions between parasite invasion ligands and their cognate red blood cell receptors, of which only a handful have been identified (1) (2) (3) (4) (5) (6) (7) . These ligand-receptor interactions initiate a cascade of molecular events that progress from initial attachment, recognition, commitment, and last, penetration of the parasite into red blood cells (8, 9) . P. vivax is the most widely distributed human malaria parasite. This parasite has a strict preference for invasion into reticulocytes, which are very young red blood cells that are formed in the bone marrow after enucleation and released into the circulation. The reticulocyte-specific receptor involved in P. vivax entry has not been identified (10) . Most studies have focused on the interaction between the P. vivax Duffy binding protein (PvDBP) and the red blood cell Duffy antigen receptor for chemokines (DARC) because individuals from western and central Africa lacking DARC are resistant to P. vivax invasion (11) . However, recent reports have highlighted the presence of P. vivax in apparently DARCnegative individuals, suggesting that P. vivax may enter reticulocytes by binding to other receptors (12) (13) (14) . Furthermore, DARC is present on both normocytes and reticulocytes, and therefore this ligand-receptor interaction cannot govern selective entry into reticulocytes (15) . To identify other parasite proteins involved in reticulocyte recognition, we focused on the P. vivax reticulocyte-binding protein family (PvRBP). This protein family comprises 11 members, of which several have been shown to bind reticulocytes; however, their cognate receptors have not been identified (16) (17) (18) (19) .
PvRBP2b binds transferrin receptor 1 to mediate recognition of reticulocytes P. vivax preferentially invades reticulocytes that express high levels of transferrin receptor 1 (TfR1 or CD71) (20) . TfR1 is an essential housekeeping protein involved in cellular transport of iron into cells through binding of iron-loaded transferrin (Tf) (21) . On circulating red blood cells, TfR1 is expressed only on reticulocytes and is progressively lost from their membranes as they mature into erythrocytes (22, 23) . TfR1 is a type II transmembrane glycoprotein that forms a dimer, and its ectodomain consists of three subdomains: a "protease-like domain" resembling the structure of zinc metalloproteinases, an "apical domain," and a "helical domain" responsible for dimerization (24) . TfR1 is also a cellular receptor for New World hemorrhagic fever arenaviruses, including Machupo (MACV), Junin, Guanarito, and Sabiá viruses (25, 26) . Residues 208 to 212 of the TfR1 apical domain provide a critical recognition site for these viruses (25, 26) .
PvRBP2b is expressed in late-stage P. vivax parasites, and recombinant PvRBP2b (residues 161 to 1454; PvRBP2b 161-1454 ) binds preferentially to reticulocytes that express TfR1 (19, 27) . We observed that binding by recombinant PvRBP2b was abolished when reticulocytes were treated with trypsin and chymotrypsin (fig. S1, A and B). We confirmed that the combination of these proteases cleaves TfR1 and complement receptor 1 (CR1) from the surface of reticulocytes, with other known malaria receptors-including glycophorin A, basigin, and DARC-being susceptible to different sets of protease treatment (fig. S1, A and B). The profile of PvRBP2b binding is strikingly similar to the TfR1 surface expression on reticulocytes (Fig. 1A, bottom) , and we show that the level of PvRBP2b binding is directly correlated with the levels of TfR1 on the surface of reticulocytes (fig. S1, C and D).
To determine whether PvRBP2b 161-1454 binds to the population of reticulocytes that express TfR1 on their surfaces, we tested a panel of commercially available anti-TfR1 monoclonal antibodies (mAbs) for their ability to block recombinant PvRBP2b binding. Indeed, anti-TfR1 mAbs 23D10, L01.1, LT71, M-A712, MEM-189, and OKT9 inhibited PvRBP2b binding to reticulocytes by 78, 76, 33, 75, 92, and 90%, respectively (Fig. 1A) . M-A712 also prevents MACV pseudovirus entry (25, 28) . Anti-TfR1 mAbs 2B6, 13E4, and MEM-75 did not inhibit PvRBP2b binding; although their epitopes have not been mapped, we propose that these three antibodies may bind to a site on TfR1 that is not involved in the PvRBP2b interaction (Fig. 1A) . To determine whether this inhibition was specific to PvRBP2b 161-1454 binding, we analyzed the binding of P. falciparum reticulocyte binding protein-like homolog 4 (PfRh4) to its cognate receptor CR1 (4). Whereas addition of the first three complement control protein modules of CR1 (CCP 1-3) inhibited PfRh4 binding as expected (29) , addition of anti-TfR1 mAb OKT9 did not significantly reduce PfRh4 binding (Fig.  1B) . Because anti-TfR1 did not affect PfRh4 binding, these results show that TfR1 is a specific reticulocyte receptor for PvRBP2b.
To evaluate whether PvRBP2b 161-1454 interacts directly with TfR1, we performed immunoprecipitation experiments using purified recombinant TfR1, Tf, and PvRBP2b 161-1454 proteins (Fig. 1C ) (30) . Using an anti-PvRBP2b mAb, we immunoprecipitated PvRBP2b in complex with TfR1 and Tf. PvRBP2b and TfR1 also formed a binary complex in the absence of Tf, demonstrating that PvRBP2b binds directly to TfR1 (Fig. 1C) . The interaction between PvRBP2b and TfR1 is specific; immunoprecipitation of PvRBP1a, PvRBP1b, or PvRBP2a did not show evidence of complex formation with TfR1 ( fig. S2A ).
We developed a fluorescence resonance energy transfer (FRET)-based assay to monitor PvRBP2b-TfR1 complex formation in which TfR1 labeled with DyLight-594 could be shown to interact with PvRBP2b 161-1454 labeled with DyLight-488 ( fig.  S2B ). The addition of 10-fold molar excess of unlabeled PvRBP2b 161-1454 and TfR1 competed out the labeled proteins and reduced the signal of the PvRBP2b-TfR1 FRET pair. By contrast, proteins that were unable to bind TfR1, such as PfRh4, had no effect on the FRET signal. Using this assay, we observed that anti-TfR1 mAbs 23D10, M-A712, MEM-189, and OKT9 that 2 of 8 inhibited PvRBP2b 161-1454 reticulocyte binding also blocked PvRBP2b-TfR1 complex formation ( Fig. 1D ).
MACV GP1 and PvRBP2b bind to the apical domain of TfR1
The arenavirus envelope glycoprotein is the only protein on the virion surface and, during maturation, is processed into three subunits: the stable signal peptide, GP1, and GP2. The GP1 subunit interacts with cellular receptors, and the structure of a MACV GP1-TfR1 complex shows that MACV GP1 binds to the apical domain of TfR1 (31, 32) . To determine whether PvRBP2b interacts with a similar surface on TfR1, we examined whether soluble MACV GP1 competes with PvRBP2b 161-1454 for binding to TfR1 on reticulocytes ( Fig. 1E) . Indeed, the addition of MACV GP1 reduced PvRBP2b 161-1454 binding to reticulocytes, albeit at a lower level of inhibition as compared with the addition of anti-TfR1 mAb MEM-189. This inhibition was specific; PfRh4 binding was unaffected by addition of MACV GP1 or MEM-189 but clearly reduced with the addition of CCP 1-3 (Fig. 1E ). The addition of MACV GP1 inhibited PvRBP2b-TfR1 complex formation and reduced the FRET signal to a similar extent as unlabeled PvRBP2b 161-1454 , whereas addition of CCP 1-3 had negligible effect (Fig. 1F) . These results indicate that MACV GP1 and PvRBP2b 161-1454 bind to an overlapping site on TfR1.
Crystal structure of the N-terminal domain of PvRBP2b
PvRBP2b is a 326-kDa protein with a putative red blood cell-binding domain and a C-terminal transmembrane region (Fig. 2) . We determined the crystal structure of the N-terminal domain of PvRBP2b (residues 169 to 470; PvRBP2b 169-470 ), refined to 1.71-Å resolution ( Fig. 2A; fig. S3 , A to D; and table S1). The surface of the domain is mostly positively charged (Fig. 2B) . It is predominantly an a-helical protein, comprising 10 a-helices and two very short antiparallel b-sheets, each comprising two b-strands. . This structure closely resembles the homologous domain of PvRBP2a and PfRh5, with a root mean square deviation of 1.7 and 3.7 Å over 268 and 225 aligned Ca atoms, respectively (Fig. 2C and fig. S4) (18, 33, 34 of the crystal structure and the ab initio calculated molecular envelope (Fig. 2D, left) . We also obtained SAXS data for a longer fragment of PvRBP2b including residues 169 to 652 (fig. S6  and table S2 ). The reconstructed molecular envelope has a rodlike shape, with a C-terminal part forming a continuous extension of the N-terminal domain (Fig. 2D, right) . SAXS data for a larger fragment of PvRBP2b encompassing residues 161 to 969 indicate that the molecule adopts an elongated, boomerang-like shape, similar to that previously reported for PvRBP2a (figs. S6, A to F, and S7, A to D, and table S2) (18) . We calculated nucleotide diversity (p) and Tajima's D within PvRBP2b using data from Gruszczyk the MalariaGEN P. vivax Genome Variation project (35) . There was a peak in both metrics between amino acid positions 169 and 470, suggesting balancing selection within the N-terminal domain (Fig. 2E ). Such signatures of balancing selection are often associated with genes or proteins expressed on the surface of merozoites and are likely due to interaction with the immune system. To determine the importance of the N-terminal domain for PvRBP2b function, we generated a series of purified recombinant PvRBP2b protein fragments ( Fig. 2F and tables S3 and S4 ). All proteins were soluble and properly folded as indicated by high a-helical content in CD spectra, which is in agreement with the secondary structure predictions ( fig. S8, A to D) . We observed that all fragments with the N-terminal domain bound reticulocytes (PvRBP2b 161-1454 , PvRBP2b 161-969 , PvRBP2b 169-813 , and PvRBP2b 169-652 ), whereas their corresponding fragments without the domain did not (PvRBP2b 474-1454 and PvRBP2b 474-969 ) (Fig. 2G) . However, the isolated N-terminal domain PvRBP2b 169-470 was unable to bind reticulocytes on its own (Fig. 2G) , indicating that this fragment of PvRBP2b is necessary but not sufficient for reticulocyte binding. The shortest PvRBP2b fragment that showed binding to reticulocytes encompasses residues 169 to 652 (Fig. 2G) . Our FRET-based assay showed that unlabeled recombinant fragments that bind reticulocytes inhibited PvRBP2b-TfR1 complex formation, whereas recombinant fragments that did not bind reticulocytes had a negligible effect (Fig. 2H) . Collectively, our structural and functional analyses indicate that the N-terminal domain is necessary for binding but requires the presence of the elongated Cterminal fragment to form a fully functional binding site.
PvRBP2b, TfR1, and Tf form a stable complex at nanomolar concentrations
Using surface plasmon resonance, we found that PvRBP2b 161-1454 interacts with TfR1 alone or with the binary complex of TfR1-Tf (Fig. 3A, top and bottom, respectively). We also observed similar results for the PvRBP2b 161-969 fragment with TfR1 and TfR1-Tf (Fig. 3B, top and bottom, respectively) . These results indicate that Tf was Gruszczyk not required for the PvRBP2b-TfR1 complex formation because the addition of Tf resulted in similar binding responses than for TfR1 alone. We analyzed a PvRBP2b, TfR1, and Tf ternary complex using analytical size exclusion chromatography (SEC) and used SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analyses to confirm comigration of complex components. The ternary complex was detected for PvRBP2b and PvRBP2b (Fig. 3, C and D (Fig. 3, C and D, bottom) . The interaction between PvRBP2b and TfR1-Tf binary complex is similar in the presence of either the irondepleted or iron-loaded form of human transferrin ( fig. S2C) . Furthermore, the homologous member of the same protein family, PvRBP2a, did not form a ternary complex with TfR1-Tf ( fig. S2D ). Sedimentation velocity analyses of TfR1, Tf, and PvRBP2b 161-969 indicated that the isolated proteins are homogenous, with weight-average sedimentation coefficients of 7.3, 4.9, and 3.6 S, respectively (Fig. 3E) . These values are consistent with a stable dimer of TfR1 and monomeric forms of both Tf and PvRBP2b 161-969 . The empirically fitted shape parameter value (frictional ratio) calculated for PvRBP2b 161-969 was~1.8, which is consistent with a highly elongated structure in solution. Mixtures of TfR1-Tf and PvRBP2b 161-969 -TfR1-Tf yielded single symmetrical peaks with weight-average sedimentation coefficients of 11.5 and 11.2 S, respectively, with no peaks observed for the individual components in these samples (Fig. 3F and fig. S9 ). These results indicate that Tf and TfR1 form a stable binary complex in solution and that PvRBP2b 161-969 binds to this binary complex. The frictional ratio (f/f 0 ) for the ternary PvRBP2b 161-969 -TfR1-Tf was higher than for the binary TfR1-Tf complex, resulting in a reduction in the sedimentation coefficient on formation of the ternary complex and indicating that it has an elongated structure in solution.
Deletions in TfR1 generated via CRISPR/Cas9 abolishes PvRBP2b binding and P. vivax invasion To investigate whether loss of TfR1 surface expression on red blood cells would affect PvRBP2b protein binding, we attempted to generate a knockout of the TFRC gene using CRISPR/Cas9 genome editing of the JK-1 erythroleukemia cell line. We obtained single-cell clones that displayed reduced expression of TfR1 and validated the mutation in two independent clones (TfR1 mut1 and TfR1 mut2) ( fig. S10, A to C) . Both clones contained an identical -3-bp deletion that resulted in the loss of amino acid Gly 217 in the TfR1 apical domain but left the rest of the protein in-frame. TfR1 mut1 was homozygous for this deletion, whereas TfR1 mut2 has a -3-bp deletion, as described above, on one allele and a -11-bp deletion on the other allele, the latter leading to a premature stop codon. Deletion of TFRC in a mouse model is embryonic lethal and leads to severe disruption of erythropoiesis (36) , suggesting that complete deletion of TFRC in erythroid-lineage cells, such as JK-1, may not be possible. Differentiated polychromatic JK-1 cells (termed jkRBCs) express surface proteins (including TfR1) at levels comparable with those of differentiated CD34 + bone marrow-derived cultured red blood cells (cRBCs) (37) . The jkRBCs, cRBCs, and differentiated jkRBCs with a knockout within the basigin receptor (DBSG) show normal levels of TfR1, whereas TfR1 mutant clones displayed an intermediate level of TfR1 surface staining, with a panel of anti-TfR1 mAbs (Fig. 4A and fig. S11 ). Levels of glycophorin A (GypA) and basigin (BSG) on these TfR1 mutant clones were similar to all control cells, showing that only TfR1 surface expression is affected on these cells (Fig. 4A) . To determine whether deletion of Gly 217 affects PvRBP2b binding, we generated a recombinant TfR1 protein that lacks this amino acid (TfR1DG217). Using SEC, we show that although TfR1DG217 was still able to bind Tf, its binding to PvRBP2b was completely abolished (Fig. 4B) . Gly
217
, which resides on the lateral surface of the TfR1 apical domain, is close to the MACV GP1 interaction surface ( fig. S10D) (31) .
To confirm that the mutation in TFRC did not result in changes in expression of other red blood cell proteins, we compared the abundance of cell surface proteins between wild-type jkRBCs and the two TfR1 mutants using tandem mass tag-based quantitative surface proteomics (Fig.  4C) . Out of 237 quantified surface proteins, only TfR1 and Tf were significantly modified, confirming the specificity of the TFRC mutations.
We next wanted to determine whether PvRBP2b binding was affected in the TfR1 mutant clones. PvRBP2b 161-1454 and PvRBP2b 161-969 bound jkRBCs and cRBCs, whereas recombinant fragments PvRBP2b 474-1454 and PvRBP2b 474-969 that lacked the N-terminal domain did not (Fig. 4D) . By contrast, we did not detect any PvRBP2b and PvRBP2b 161-969 binding to TfR1 mutant cells. This abolition of binding was specific to deletions in TFRC because PvRBP2b binding was unaffected on DBSG null cells or on cRBCs (Fig. 4D, right) . We also compared the invasion efficiency between jkRBCs and TfR1 mutant cell lines with either Brazilian P. vivax isolates or P. falciparum 3D7 (fig. S10E) . A significant (>10-fold) reduction in invasion efficiency was observed in the TfR1 mutant line compared with the jkRBCs line with P. vivax, whereas no significant difference was observed with P. falciparum (Fig. 4E) . These results validate TfR1 as the cognate receptor for PvRBP2b and that TfR1 is an essential host factor for P. vivax invasion.
Antibodies to PvRBP2b block reticulocyte binding and P. vivax invasion To examine whether PvRBP2b antibodies could inhibit P. vivax invasion, we raised mouse monoclonal antibodies to PvRBP2b 161-1454 and obtained four mAbs. 3E9, 6H1, and 10B12 bound epitopes within the N-terminal domain present in PvRBP2b 169-470 with high affinities (Fig. 5A;  fig. S12 , A to C; and table S6), whereas mAb 8G7 recognized an epitope outside the N-terminal domain within amino acids 813 to 969 (Fig. 5A) . Competition enzyme-linked immunosorbent assay (ELISA) experiments using mAbs directly conjugated to horseradish peroxidase (HRP) show that each mAb only competed with itself for binding to PvRBP2b, showing that 3E9, 6H1, and 10B12 bind to distinct epitopes in the N-terminal domain (Fig. 5B) . Neither polyclonal nor monoclonal antibodies to PvRBP2b recognize recombinant PfRh4 and five other recombinant PvRBPs, indicating that these antibodies are specific to PvRBP2b ( fig. S12B) (19) . Using flow cytometry, we show that addition of anti-PvRBP2b mAbs 3E9, 6H1, and 10B12 abolished the PvRBP2b 161-1454 binding to reticulocytes, whereas anti-PvRBP2b mAb 8G7 and anti-PvRBP2a mAb 3A11 had no effect (Fig. 5C ).
WetestedtheabilityoftheantibodiestoPvRBP2b to inhibit P. vivax invasion into human reticulocytes, using a short-term P. vivax ex vivo assay with Brazilian and Thai clinical isolates (Fig. 5D , blue and black open circles, respectively). As a control, we used a camelid antibody to Fy6, which is a single monovalent VHH domain (15 kDa) (38, 39) that targets a surface-exposed epitope on DARC and blocks its interaction with PvDBP. The addition of the 25 mg/ml camelid antibody to Fy6 in ex vivo assays by using Thai isolates resulted in 85% inhibition of P. vivax invasion (Fig. 5D ). Using four Thai isolates, the addition of inhibitory anti-PvRBP mAbs 3E9, 6H1, and 10B12 at 25 mg/ml resulted in 49, 45, and 42% inhibition of P. vivax invasion, respectively. To determine whether inhibition could be improved by increasingthe concentration ofanti-PvRBP2bmAbs to match the molarity and valency of the single VHH domain, we used 125 mg/ml of inhibitory anti-PvRBP2b mAbs. Under these conditions, we tested the invasion efficiency of two Brazilian isolates. We observed that addition of inhibitory anti-PvRBP mAbs 3E9, 6H1, and 10B12 at 125 mg/ml resulted in 68, 45, and 57% inhibition of P. vivax invasioninBrazilian isolates,respectively (Fig.5D) . To enable quantitative analyses of the ex vivo assays, we combined our initial results of Thai and Brazilian isolates attheir respective mAb concentrations. Increased concentration of the inhibitory anti-PvRBP2b mAbs resulted in an equivalent or small increase in inhibition of P. vivax invasion (Thai at 25 mg/ml versus Brazilian at 125 mg/ml). Thus, our combined sample set underestimates the level of inhibition for antibody concentrations of 125 mg/ml. As additional controls, we included the noninhibitory anti-PvRBP2b mAb 8G7 and an immunoglobulin G1 (IgG1) mouse isotype control, which displayed only 8 and 9% inhibition of P. vivax invasion, respectively (Fig. 5D) . These results show that addition of anti-PvRBP2b inhibitory mAbs 3E9, 6H1, and 10B12 resulted in significant reduction of P. vivax invasion compared with the noninhibitory anti-PvRBP2b mAb 8G7 (Fig. 5D) .
We show that the inhibitory anti-PvRBP2b mAbs target a domain that appears to be under balancing selection (Figs. 2E and 5A ), which may result in differences in inhibition between clinical isolates owing to the presence of polymorphic epitopes. To circumvent inter-isolate differences, we further tested the combination of all three inhibitory mAbs, 3E9, 6H1, and 10B12 pooled together (mAb pool) and polyclonal antibodies to PvRBP2b. The mAb pool resulted in significant 48% reduction in P. vivax invasion in both Thai and Brazilian isolates compared with that of antiPvRBP2b mAb 8G7 (Fig. 5D) . Addition of purified total IgG of polyclonal antibodies to PvRBP2b R1527 resulted in 53% reduction in P. vivax invasion, whereas the rabbit prebleed IgG showed only 5% inhibition (Fig. 5D) . A previous study using rabbit antibodies to PvDBP shows that P. vivax invasion was reduced up to 64% (40), a level of inhibition comparable with what has been observed with our antibodies to PvRBP2b (Fig. 5D) . These results show that anti-PvRBP2b mAbs that block binding to reticulocytes also inhibit P. vivax invasion and highlight the important role of the PvRBP2b-TfR1 invasion pathway in P. vivax field isolates.
Our results reveal a stable interaction between PvRBP2b and TfR1 and that antibodies to PvRBP2b that block binding to reticulocytes also inhibit P. vivax invasion into human reticulocytes. P. vivax invasion is significantly inhibited in the presence of TfR1 mutant cells, showing that TfR1 is a critical host factor for entry into reticulocytes. We propose that the PvRBP2b-TfR1 interaction is important for the initial recognition of the target reticulocyte cells, which results in the commitment of P. vivax parasites for reticulocyte invasion and the subsequent engagement of PvDBP-DARC in tight junction formation, leading to the successful completion of the invasion process. Identification of the molecular entities required for P. vivax invasion offer the possibility to target multiple invasion pathways for synergistic inhibition of P. vivax blood stage infection.
